Structured Diagnostic Approach Guides Management of Chronic Diarrhea

Navigating the Diagnostic Maze of Persistent Diarrhea

Outpatient clinicians frequently encounter gastrointestinal complaints, necessitating a clear distinction between self-limiting infections and chronic pathologies. Chronic diarrhea, defined as loose or watery stools persisting for more than four weeks, affects approximately 6% to 7% of adults in the United States, with more than 90% of these cases attributed to noninfectious etiologies [1]. The diagnostic process is often complex, requiring a balance of serological testing and endoscopic evaluation to rule out malignancy or autoimmune disease [1]. This challenge is compounded by the gut microbiome, a dense ecosystem of 38 trillion bacterial cells weighing approximately 0.2 kilograms in the average adult, which influences bowel motility and fluid absorption [2]. While many cases are functional, meta-analytic data suggest specific probiotics like Saccharomyces boulardii can be effective in certain contexts, reducing the risk of antibiotic-associated diarrhea with a relative risk of 0.47 (95% confidence interval 0.35 to 0.63, p < 0.001) [1, 3].

Differentiating Small-Bowel and Colonic Pathologies

The primary clinical task in evaluating noninfectious diarrhea is distinguishing between irritable bowel syndrome with diarrhea (IBS-D) and functional diarrhea. The most common causes of chronic, noninfectious diarrhea are IBS-D and functional diarrhea, and the presence of abdominal pain is the key diagnostic pivot. IBS-D typically presents with recurrent abdominal pain that is either relieved or worsened by defecation, whereas functional diarrhea is not associated with significant abdominal pain. Specifically, functional diarrhea is defined as a condition where more than 25% of bowel movements over the preceding three months are loose or watery without the hallmark pain of irritable bowel syndrome. Identifying this relationship early allows physicians to categorize the patient’s condition without immediately resorting to invasive testing.

When symptoms suggest an organic rather than functional cause, clinicians must localize the source to the small bowel or the colon. Chronic diarrhea originating from a small-bowel source, such as celiac disease or small intestinal bacterial overgrowth, is typically associated with large-volume stools and weight loss, often accompanied by steatorrhea (the presence of excess fat in the stool indicating malabsorption). Celiac disease is an autoimmune condition characterized by enteropathy (pathological damage to the intestinal lining) triggered by dietary gluten in genetically susceptible individuals. Similarly, small intestinal bacterial overgrowth involves an abnormal increase in the bacterial population within the small intestine, which interferes with nutrient absorption and leads to high-volume diarrhea.

In contrast, colonic pathologies present with a distinct pattern of frequent, low-volume stools. Chronic diarrhea due to colon pathology, such as bile acid diarrhea and microscopic colitis, typically presents with frequent, low-volume stools, with or without urgency and excess mucus. Bile acid diarrhea occurs when an excess of bile acids reaches the colon, acting as a secretagogue (a substance that stimulates the secretion of another substance) that increases fluid secretion and motility. Microscopic colitis is characterized by chronic inflammation that is only detectable on histological examination of colon biopsies, as the endoscopic appearance of the mucosa often remains normal. Recognizing these low-volume, high-frequency patterns is clinically vital, as it directs the physician to perform biopsies even when the colon appears visually healthy during a colonoscopy.

Targeted Testing and Endoscopic Red Flags

A structured diagnostic workup is essential to identify treatable organic conditions. Diagnostic testing should include consideration of celiac disease, inflammatory bowel disease, and microscopic colitis, using specific biomarkers to guide the investigation. Evaluation of chronic diarrhea includes serological testing for celiac disease using tissue transglutaminase immunoglobulin A (an antibody test that identifies the primary autoimmune marker of the disease), along with total immunoglobulin A. Measuring total immunoglobulin A is a critical clinical step to ensure that a negative tissue transglutaminase result is not a false negative caused by a concurrent, underlying immunoglobulin A deficiency. Additionally, stool testing for fecal calprotectin (a protein released by neutrophils that serves as a marker for intestinal inflammation) should be used to evaluate for inflammatory bowel disease. This allows clinicians to differentiate between inflammatory states and functional disorders before committing to invasive procedures.

Certain clinical alarm features mandate immediate referral for endoscopic evaluation to rule out malignancy or severe structural disease. Patients with gastrointestinal bleeding, unexplained weight loss, age 45 years or older, nocturnal diarrhea, steatorrhea, or iron deficiency anemia should undergo colonoscopy to evaluate for colorectal cancer as well as upper endoscopy. Visual inspection during these procedures is often insufficient for a definitive diagnosis. During colonoscopy, random biopsies are recommended to evaluate for microscopic colitis, a condition that cannot be seen by the naked eye during the procedure. This step is essential for the practicing physician to remember, as microscopic colitis affects 13% of patients with chronic diarrhea. Without these random tissue samples, a significant portion of patients may remain undiagnosed, leading to persistent symptoms and unnecessary repeat testing.

Empiric Management and Lifestyle Interventions

If a thorough diagnostic evaluation fails to reveal an organic etiology, the patient is likely suffering from a functional disorder such as IBS-D or functional diarrhea. Management begins with structured lifestyle interventions designed to stabilize gut motility. Physicians should counsel patients on maintaining regularly scheduled meals, engaging in consistent physical exercise, and ensuring a daily intake of at least 8 cups of noncaffeinated fluids. Furthermore, patients should be advised to limit caffeine to 3 cups or fewer per day and to avoid common triggers such as alcohol and carbonated beverages, which can exacerbate osmotic load and intestinal transit speed.

For patients who do not respond to lifestyle changes alone, dietary and pharmacological therapies are the next step. Dietary modification focuses on a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (a group of short-chain carbohydrates known as FODMAPs that are poorly absorbed and fermented by gut bacteria, leading to gas and fluid secretion). Specifically, this involves reducing intake of legumes, wheat, onions, garlic, lactose, fructose, and sugar alcohols like sorbitol or mannitol. If dietary shifts are inadequate, pharmacological options include opiate agonists such as loperamide to slow transit, anticholinergics like hyoscyamine or dicyclomine to reduce spasms, or 5-hydroxytryptamine 3 receptor antagonists (medications such as ondansetron that block serotonin receptors in the gut to decrease motility and secretion). These empiric therapies, which include lifestyle and dietary modifications along with medications, typically improve diarrhea in 50% to 80% of patients, providing a high probability of symptomatic relief for those with functional bowel disorders.

References

1. Singh P, Lee AA, Sheth N, Chey WD. Chronic, Noninfectious Diarrhea: A Review.. 2026. doi:10.1001/jama.2026.0872

2. Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biology. 2016. doi:10.1371/journal.pbio.1002533

3. McFarland LV. Systematic review and meta-analysis ofSaccharomyces boulardiiin adult patients. World Journal of Gastroenterology. 2010. doi:10.3748/wjg.v16.i18.2202